文献速递骨质疏松与代谢性骨病脊柱外科

肝酶诱导性抗惊厥药物使用与椎体骨折患病率相关

Liver enzyme inducing anticonvulsant drug use is associated with prevalent vertebral fracture.
PubMed 文献 · Osteoporos Int · 2023-06-28

研究纳入11822例接受骨密度检查及椎体骨折评估(VFA)的个体(平均年龄76.1岁,94%女性),分析既往抗惊厥药物暴露与椎体骨折患病的关系。结果示肝酶诱导(LEI)抗惊厥药使用≥2年者椎体骨折患病率为27.0%,校正后OR 1.48(95%CI 1.04, 2.10)。作者认为对使用LEI抗惊厥药≥2年的老年人,骨密度检查时行侧位脊柱VFA可能合适。

要点

  • LEI抗惊厥药使用≥2年者椎体骨折患病率为27.0%。
  • 校正多变量后LEI抗惊厥药≥2年与椎体骨折相关(OR 1.48,95%CI 1.04, 2.10)。
  • 对使用LEI抗惊厥药≥2年的老年人,骨密度检查时行VFA可能合适。

核心结论

  • LEI抗惊厥药使用≥2年与更高的椎体骨折患病率相关。
  • 作者认为对使用LEI抗惊厥药≥2年的老年人,骨密度检查时行侧位脊柱VFA可能合适。

研究设计与样本

  • 研究人群为2010年至2018年间接受骨密度检查及VFA的11822例个体,平均年龄76.1岁(标准差6.8),94%为女性。
  • 通过关联药房记录确定既往LEI抗惊厥药(卡马西平、苯巴比妥、苯妥英、丙戊酸,n=538)、非LEI抗惊厥药(氯硝西泮、加巴喷丁、左乙拉西坦等,n=2786)及其他非氯硝西泮苯二氮䓬类药物(n=5082)的累积暴露。
  • 采用改良ABQ法在VFA图像上识别椎体骨折,并使用逻辑回归模型估计抗惊厥药物暴露与椎体骨折的关联。

主要发现

  • 整个分析队列中一个或多个椎体骨折的患病率为16.1%。
  • 既往LEI抗惊厥药使用≥2年者椎体骨折患病率为27.0%,非LEI抗惊厥药使用者为19.0%,其他苯二氮䓬类药物使用者为18.5%。
  • 校正多个协变量后,既往LEI抗惊厥药使用≥2年与VFA上的椎体骨折相关(OR 1.48,95%CI 1.04, 2.10)。

关键数值与推荐

  • 既往LEI抗惊厥药使用≥2年者椎体骨折患病率为27.0%。
  • 校正后LEI抗惊厥药使用≥2年与椎体骨折的OR为1.48(95%CI 1.04, 2.10)。

临床怎么用

  • 作者认为对使用LEI抗惊厥药≥2年的老年人,骨密度检查时行侧位脊柱VFA可能合适。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Among those who use of liver-enzyme inducing anticonvulsant medication for more than 2 years, 27% have a prevalent vertebral fracture on vertebral fracture assessment (VFA) lateral spine imaging. VFA imaging at the time of bone densitometry may be appropriate for older individuals who are chronic users of these medications. PURPOSE: It is unclear whether prevalent vertebral fractures are associated with use of anticonvulsant drugs, especially those that induce liver enzymes (LEI) that metabolize drugs and vitamin D. Our purpose was to estimate the prevalence of vertebral fracture on densitometric lateral spine images according to duration of prior anticonvulsant medication use. METHODS: Our study population was 11,822 individuals (mean [sd] age 76.1 [6.8] years, 94% female) who had bone densitometry with VFA between 2010 and 2018. Cumulative prior exposure to LEI anticonvulsants (carbamazepine, phenobarbital, phenytoin, valproic acid, n = 538), non-LEI anticonvulsants (clonazepam, gabapentin, levetiracetam, others, n = 2786), and other non-clonazepam benzodiazepines (n = 5082) was determined using linked pharmacy records. Prevalent vertebral fractures were identified on VFA images using the modified ABQ method. Logistic regression models were used to estimate the association of anticonvulsant drug exposure with prevalent vertebral fractures. RESULTS: Prevalence of one or more vertebral fractures was 16.1% for the entire analytic cohort, and 27.0%, 19.0%, and 18.5% for those with ≥ 2 years of prior LEI anticonvulsant use, non-LEI anticonvulsant use, and other benzodiazepine use, respectively. Adjusted for multiple covariates, use of prior LEI anticonvulsant medication for ≥ 2 years was associated with prevalent fracture on VFA (OR 1.48 [95% CI 1.04, 2.10]). CONCLUSION: LEI anticonvulsant use for ≥ 2 years is associated with higher vertebral fracture prevalence. Lateral spine VFA imaging at the time of bone densitometry may be appropriate for older individuals who have used LEI anticonvulsant medications for ≥ 2 years.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Schousboe JT, Binkley N, Leslie WD, et al. Liver enzyme inducing anticonvulsant drug use is associated with prevalent vertebral fracture. Osteoporos Int. 2023. PMID: 37380883. doi:10.1007/s00198-023-06820-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。